RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
BackgroundAdjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits.How to balance its potential benefits and risks becomes a challenging clinical problem.The purpose of this study was to assess whether RecurIndex assa